Ovarian Cancer
Late last year, the PARP inhibitor Zejula was approved by the FDA for patients with HRD mutation associated with advanced ovarian, fallopian tube, or primary peritoneal cancer, offering a new treatment option for women with these types of cancer. Read More ›
There are a number of excellent organizations providing resources and support to you as a patient with ovarian cancer or a caregiver. Read More ›
As a retired college professor, Dr. McElhiney uses her personal experience with ovarian cancer to advocate for other patients, urging faster development of new treatment options. Read More ›
In her Introduction to the special edition of CONQUER titled Understanding Biomarkers & Molecular Testing, Lillie D. Shockney, RN, BS, MAS, ONN-CG, briefly explains what biomarkers are, why they are important, and what you should know about them. Read More ›
Dr. Julian Schink, GYN Oncology Chief of Cancer Treatment Centers of America, provides screening tips and recommendations for these 2 most common gynecologic cancers. Read More ›
In August 2017, the FDA approved Lynparza tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a response to platinum-based chemotherapy. Read More ›
Ovarian cancer ranks fifth in cancer-related deaths in women, accounting for more deaths than any other cancer of the female reproductive system. Read More ›
In 1997 I was 27, happy, free, and traveling the world as a flight attendant. Newly married and ready to have a baby, I felt strong and invincible. My future was unfolding just as I expected it to. Until the symptoms appeared ever so subtly. Read More ›
A look at how Roberta Aberle deals with the fact that cancer runs in her family. Read More ›